A Phase 2 interventional study of ZD4054 Zibotentan and Paclitaxel in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy, sponsored by AstraZeneca. Terminated at 20 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-07.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare progression-free survival in patients with advanced ovarian cancer treated with ZD4054 in combination with carboplatin+paclitaxel versus placebo in combination with carboplatin+paclitaxel.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 120 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZD4054 10mg oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
Drug: ZD4054 Zibotentan · Drug: Paclitaxel · Drug: Carboplatin
Placebo oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
Drug: Paclitaxel · Drug: Carboplatin · Drug: Placebo
10 mg oral tablets once daily
175mg/m2 IV on day 1 every 3 weeks
Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
matching placebo for ZD4054 10 mg
Progression Free Survival
Median time (in months) from randomisation until clinical progression of disease using the Kaplan-Meier method.
Time frame: Patients were followed for progression up to 2 years
Overall Survival
Median time (in months) from randomisation until death using the Kaplan-Meier method.
Time frame: Patients were followed for survival up to 2 years
Tumour Response Rate
Objective response rate defined as participants with a complete or partial response according to RECIST
Time frame: While receiving paclitaxel + carboplatin study visits were aliged with its administration ie every 3 weeks, then every 6 weeks (up to 2 years)
132 patients with advanced ovarian cancer sensitive to platinum-based chemotherapy were recruited between 26th June 2009 and 1st June 2011.
| Milestone | ZD4054+Paclitaxel+Carboplatin | Placebo+Paclitaxel+Carboplatin |
|---|---|---|
| Started | 59 | 61 |
| Patients who received treatment | 58 | 58 |
| Completed | 11 | 19 |
| Not completed | 48 | 42 |
| Withdrew: Adverse event | 8 | 5 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Protocol violation | 32 | 30 |
| Withdrew: Other termination reason | 5 | 6 |
Median time (in months) from randomisation until clinical progression of disease using the Kaplan-Meier method.
| Months | ZD4054+Paclitaxel+Carboplatin | Placebo+Paclitaxel+Carboplatin |
|---|---|---|
| Progression Free Survival | 7.6 (6.6 to 10.2) | 10.0 (7.1 to 12.2) |
Median time (in months) from randomisation until death using the Kaplan-Meier method.
No measurements were reported for this outcome.
Objective response rate defined as participants with a complete or partial response according to RECIST
| Participants | ZD4054+Paclitaxel+Carboplatin | Placebo+Paclitaxel+Carboplatin |
|---|---|---|
| Tumour Response Rate | 21 | 34 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZD4054+Paclitaxel+Carboplatin | — | 19/58 (32.8%) | 57/58 (98.3%) |
| Placebo+Paclitaxel+Carboplatin | — | 13/58 (22.4%) | 58/58 (100%) |
| Event | ZD4054+Paclitaxel+Carboplatin | Placebo+Paclitaxel+Carboplatin |
|---|---|---|
| Drug HypersensitivityImmune system disorders | 5/58 | 4/58 |
| Abdominal PainGastrointestinal disorders | 4/58 | 1/58 |
| SubileusGastrointestinal disorders | 4/58 | 0/58 |
| IleusGastrointestinal disorders | 3/58 | 0/58 |
| ConstipationGastrointestinal disorders | 2/58 | 1/58 |
| PyrexiaGeneral disorders | 0/58 | 2/58 |
| AnaemiaBlood and lymphatic system disorders | 1/58 | 0/58 |
| Coronary Artery OcclusionCardiac disorders | 0/58 | 1/58 |
| Ischaemic CardiomyopathyCardiac disorders | 0/58 | 1/58 |
| AscitesGastrointestinal disorders | 1/58 | 1/58 |
| Event | ZD4054+Paclitaxel+Carboplatin | Placebo+Paclitaxel+Carboplatin |
|---|---|---|
| NauseaGastrointestinal disorders | 28/58 | 31/58 |
| AnaemiaBlood and lymphatic system disorders | 30/58 | 25/58 |
| AlopeciaSkin and subcutaneous tissue disorders | 28/58 | 28/58 |
| FatigueGeneral disorders | 20/58 | 27/58 |
| HeadacheNervous system disorders | 27/58 | 17/58 |
| NeutropeniaBlood and lymphatic system disorders | 26/58 | 22/58 |
| ConstipationGastrointestinal disorders | 24/58 | 19/58 |
| VomitingGastrointestinal disorders | 21/58 | 20/58 |
| LeukopeniaBlood and lymphatic system disorders | 20/58 | 15/58 |
| Abdominal PainGastrointestinal disorders | 16/58 | 20/58 |
| Age Continuous(Years) | ZD4054+Paclitaxel+Carboplatin | Placebo+Paclitaxel+Carboplatin | Total |
|---|---|---|---|
| Overall | 57.4 ± 11.98 | 56.6 ± 11.07 | 57.0 ± 11.49 |
| Sex: Female, Male(Participants) | ZD4054+Paclitaxel+Carboplatin | Placebo+Paclitaxel+Carboplatin | Total |
|---|---|---|---|
| Female | 59 | 61 | 120 |
| Male | 0 | 0 | 0 |
The record gives a start of Jun 2009, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZD4054